Loading...
DOCUMENTS
21
NOTICES
32
MOTS CLES
Inflammatory bowel diseases
Thérapie ciblée
Tailored therapy
Venous thromboembolism
Dysbiosis
Neoadjuvant chemotherapy
Safety
Resistance
Heart disease risk factors
Upper gastrointestinal tract
DNA METHYLATION
Rituximab
DNA methylation
Vedolizumab
Dysbiose
Epigenetics
Inclusion
Clinical trial
Epigénétiques
Maintenance therapy
Drug
Inflammatory Bowel Diseases
Helicobacter pylori
Methylation
Colon cancer
Intestinal crypts
Gene expression
Résistance
Biomarker
RISK
Biologics
Survival
Monitoring
Stricture
Bactéries
Consensus
Screening
Kidney diseases
MARKER
HIV
Cost effectiveness
Crohn’s disease
Clinical guidelines
Anti-TNF
IBD
18 FDG-PET/CT
Effectiveness
Colorectal cancer Colibactin and lipids
Contraindication
Immunosuppressant
Disease progression
Cell adhesion
Acceptability
Ulcerative colitis
Ustekinumab
Méthylation
Immune cells
T1118 translocation
Patient-reported outcome
Colon
MICROBIOTA
Bacteria
Algorithm
Tuberculosis
IL23
Gènes
Rituximab plus chlorambucil
Microbiote
Colonic epithelial primary cells
CARCINOGENESIS
Over 80s
Endoscopic treatment
MALT
Surgery
Disease Progression
Original Article Clinical
Inflammatory bowel disease
Alkylating agents
Eradication
Anti-TNF agents
Cancer
Gene methylation
Inhibitor
Crohn's disease
IL12
Small molecules
Fecal microbiota
Microbiota
Disability
Therapeutics
COLON-CANCER
Genes
Patients experience
PCR
Primary sclerosing cholangitis
Eligibility
MORTALITY
Colorectal cancer
Colectomy
Parvimonas micra
Early detection of Colon Cancer using Molecular Markers and Microbiota , EA 7375 | |
---|---|
Institutions |
UPEC |
Adresse |
Université Paris-Est Créteil Groupe Hospitalier Henri Mondor Service de Gastroentérologie 51 Av Maréchal de Lattre de Tassigny 94010 Créteil cedex |
Courriel |
|
Site Internet |
|
Rattachement(s) |
|
Direction |
Aurélien AMIOT |
Adjoint |
Iradj SOBHANI |
Axe(s) de recherche
|
Le laboratoire axe ses recherches sur le rôle du microbiome intestinal ainsi que des changements épigénétiques dans l'intestin afin :
|